Business context and reporting period
Novelos Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2013. The request identifies Cellectar Biosciences, Inc.; the filing itself names Novelos as registrant and describes Cellectar as its acquired business. Novelos is a development-stage cancer drug company with no product revenue. Its programs include LIGHT (PET imaging, Phase 1–2 trials ongoing), HOT (radiotherapeutic, Phase 1b ongoing), and GLOW2 (preclinical optical imaging).
Financial performance and position
- Revenue and margins: No revenue was reported. Operating loss was $2.712 million; operating margin is not meaningful without revenue.
- Loss: Net loss was $3.454 million, or $0.07 per share, versus $2.357 million, or $0.06 per share, in Q1 2012.
- Expenses: R&D was $1.591 million, up 20% from $1.328 million; G&A was $1.122 million, up 12% from $0.998 million.
- Cash flow: Operating activities used $1.889 million, compared with $1.703 million in Q1 2012. Investing activities provided $29,000, including a $122,000 reduction in restricted cash; financing activities provided $5.045 million, primarily from the February stock offering.
- Liquidity: Cash and equivalents were $7.862 million at March 31, 2013, excluding $1.878 million in restricted cash designated for a proposed LIGHT manufacturing facility. Working capital was $1.517 million; total assets were $14.312 million.
- Debt and liabilities: Notes payable were $450,000, with additional minimal capital lease obligations. Total liabilities were $7.181 million, including a $5.727 million warrant derivative liability.
- Equity and dilution: Stockholders’ equity was $7.131 million. Shares outstanding rose from 46.398 million at year-end to 57.398 million at quarter-end. The company reported 36.782 million outstanding warrants and 6.292 million options.
Material changes versus Q1 2012 and year-end 2012
- Net loss increased by $1.097 million year over year. Higher R&D reflected manufacturing and trial-related costs, payroll, and evaluation of manufacturing options; clinical project costs fell as trial start-up costs declined.
- Q1 2013 included a $745,000 noncash loss on issuance of derivative warrants, compared with none in Q1 2012. The company also recorded a $6,000 warrant revaluation gain, versus a $29,000 loss in Q1 2012.
- In February 2013, the company raised $5.5 million gross, or $4.975 million net, by issuing 11.0 million shares and warrants to purchase up to 16.5 million shares. The new down-round-protected warrants were classified as derivative liabilities.
- Compared with December 31, 2012, cash increased by $3.185 million, while the derivative liability rose from $13,000 to $5.727 million. Accumulated deficit increased to $43.731 million.
Outlook, risks, contingencies, and unusual items
- Management expected available cash, excluding restricted funds, to support operations through the end of 2013. Continued operations beyond then depend on additional financing, a strategic transaction, or other funding; there is no assurance funding will be obtained.
- The company expected continued operating losses and reported a $43.731 million accumulated deficit. It identifies financing needs, clinical and regulatory uncertainty, manufacturing arrangements, competition, and possible faster-than-planned cash consumption as key risks.
- The company was evaluating contract manufacturers for larger-scale LIGHT production and was not then pursuing construction of its own facility. The filing describes the designated manufacturing funds and the estimated facility cost as $1.878 million and $3.0 million, respectively.
- Management expected to submit a GLOW2 investigational new drug application in Q4 2013 and begin trials thereafter. LIGHT trials continued across 11 solid-tumor indications, with initial positive imaging results described for lung and brain cancers; these are company-reported development updates, not evidence of approval or commercial success.
- A ZAO BAM dispute remained on appeal after a trial-court judgment favorable to Novelos; management did not expect a material adverse financial effect. The filing also reports effective disclosure controls and no material first-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the registrant and corporate identity: this filing is by Novelos Therapeutics, Inc., although the request names Cellectar Biosciences, Inc.
- Assess the cash runway and financing assumptions, including the treatment and intended use of restricted cash and the status of financing alternatives.
- Review the terms, potential dilution, and fair-value assumptions for the February offering warrants and the $5.727 million derivative liability.
- Check subsequent clinical, regulatory, and manufacturing developments for LIGHT, HOT, and GLOW2, including the stated GLOW2 IND timeline.
- Monitor the ZAO BAM appeal and confirm whether any material change in the litigation or other contingencies has occurred.